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Background. A number of infectious agents have previously been suggested as risk factors for the development of Guillain-
Barre´ syndrome (GBS), but robust epidemiologic evidence for these associations is lacking. Methods and Findings. We
conducted a nested case-control study using data from the United Kingdom General Practice Research Database between 1991
and 2001. Controls were matched to cases on general practice clinic, sex, year of birth and date of outcome diagnosis in their
matched case. We found positive associations between GBS and infection with Campylobacter, Epstein-Barr virus and
influenza-like illness in the previous two months, as well as evidence of a protective effect of influenza vaccination. After
correction for under-ascertainment of Campylobacter infection, the excess risk of GBS following Campylobacter enteritis was
60-fold and 20% of GBS cases were attributable to this pathogen. Conclusions. Our findings indicate a far greater excess risk
of GBS among Campylobacter enteritis patients than previously reported by retrospective serological studies. In addition, they
confirm previously suggested associations between infection due to Epstein-Barr virus infection and influenza-like illness and
GBS. Finally, we report evidence of a protective effect of influenza vaccination on GBS risk, which may be mediated through
protection against influenza disease, or result from a lower likelihood of vaccination among those with recent infection. Cohort
studies of GBS incidence in this population would help to clarify the burden of GBS due to influenza, and any potential
protective effect of influenza vaccination.
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Influenza and Epstein-Barr Virus in the General Practice Research Database. PLoS ONE 2(4): e344. doi:10.1371/journal.pone.0000344
INTRODUCTION
Guillain-Barre´ syndrome (GBS) is the most common cause of acute
flaccid paralysis in polio-free regions, with incidence estimated at
between 0.4 and 4 per 100,000 in different settings [1]. The disease
has an autoimmune pathology; following infection, antibodies
produced against pathogen surface structures cross-react with nerve
ending antigens, leading to neurologic damage. Several pathogens
are thought to trigger GBS, primarily Campylobacter jejuni. Numerous
studies have demonstrated evidence for an association between GBS
and preceding C. jejuni infection. These studies have mostly relied on
serologic evidence of C. jejuni infection, reporting infection
prevalences of 15% to 66% among GBS cases compared with 0%
to 17% in controls [2–11], and odds ratios between three and five
[3,6]. However, serologic tests are not specific for recent C. jejuni
infection. These studies are thus difficult to interpret; seropositivity
could indicate recent infection, past infection, or immunity, and the
distribution of these is likely to differ between seropositive cases and
seropositive controls, leading to biased estimates of the Campylobacter-
GBS association. A Swedish capture-recapture study reported a GBS
incidence of 3.0 per 10,,000 among Campylobacter enteritis cases
reported to national surveillance, 100 times the incidence of GBS in
the general population [12]. Using data from a cohort of patients
presenting to primary care, we have previously estimated that for
every 10,000 cases of Campylobacter enteritis, two cases of GBS occur
within the two months following infection, an incidence 77 times
greater than that in the general population [13,14]. Our previous
studies have indicated that between nine and 14 percent of GBS
cases are attributable to symptomatic Campylobacter infection [13,14],
suggesting that asymptomatic infection, or infection with other
pathogens, must account for the majority of GBS cases.
Other pathogens suggested to trigger GBS include cytomega-
lovirus [8,15], Epstein-Barr virus (EBV), Haemophilus influenzae
[16,17], Mycoplasma pneumoniae [18] and influenza [19–23]. Recent
work in England using time-series methods has identified
associations between numbers of weekly reports of laboratory-
confirmed infections with Campylobacter, M. pneumoniae and in-
fluenza, and incidence of hospitalization for GBS in subsequent
weeks [24]. In the United States, influenza vaccination during
1976–1977 was associated with a seven-fold excess risk of GBS in
the subsequent six-week period [25], and polio vaccination has
been suggested as a risk factor for GBS in Finland and China
[26,27]. A recent study in England, however, found no association
between any vaccination and subsequent GBS risk [28].
In order to better define the excess risk of GBS associated with
these exposures, we undertook a nested case-control analysis in
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a United Kingdom-based general practice setting using data from
the General Practice Research Database.
METHODS
General Practice Research Database
The General Practice Research Database (GPRD) constitutes
several hundred general practice clinics (GP clinics) serving a 5%
representative sample of the UK population. The characteristics of
this data source have been previously described [29]. The
database holds electronic records of all patients registered with
participating clinics, including basic patient information (birthdate,
sex, registration and de-registration dates, death date) and records
of all consultations with corresponding diagnoses, preventions (e.g.
immunizations, screening) and prescriptions. Approval for the
study was obtained from the scientific and ethics advisory group of
the GPRD.
Data from participating clinics are validated to ensure accuracy
and completeness for a minimum set of variables. Data meeting
minimum quality criteria are termed ‘up-to-standard’ (UTS) data
and are a general indicator of the overall quality of data from
a given clinic [29]. Data from any clinic not meeting UTS criteria
were excluded. We define an individual’s up-to-standard follow-up
time as the time during which they were registered with a clinic
reporting UTS data.
GPRD diagnoses are recorded using Read or Oxmis (Oxford
Medical Information Systems) codes, standardized terms used by
medical practitioners to record patient outcome or management
information, such as medical diagnoses, symptoms, test results and
family history. We obtained information on all first consultations
for GBS occurring between 1990 and 2001. A consultation is
defined as any contact between a patient and the clinic services
that appears in their medical records. We excluded repeat
consultations. For these patients, we extracted all consultations
for these infections: Campylobacter, cytomegalovirus, Epstein-Barr
virus, H. influenzae, M. pneumoniae and influenza-like illness (ILI).
We also included two sets of non-specific codes for infectious
intestinal disease (IID) and acute respiratory infection (ARI) of
unspecified aetiology. Finally, we obtained records of all influenza
and polio vaccinations administered to GBS patients. A list of all
diagnostic codes used is available from the authors.
Cases were defined as individuals with a first GBS consultation
within their UTS follow-up time. Cases with under one year of
UTS time available were excluded. We also excluded GBS con-
sultations occurring within four months of patients’ registration
with their clinic or on the same day as a ‘‘new patient screening’’
to avoid inclusion of prevalent GBS recorded on joining a new
clinic [30].
We randomly selected 10 controls per case, matched on GP
clinic, sex, birth year (within one year for cases aged under 16
years or within five years otherwise) and GBS consultation date.
We matched on the latter because the risk period for GBS
following infection is short and some of the pathogens are highly
seasonal. For each control, we assigned a pseudo-outcome date–
the date of GBS consultation in their matched case. Controls were
excluded if they had under one year of UTS time available or their
pseudo-outcome date was within four months of clinic registration.
Figure 1 presents details of case and control exclusions.
Figure 1. Case and control exclusions.
doi:10.1371/journal.pone.0000344.g001
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Statistical analysis
The risk period forGBS following infection is thought to be only a few
weeks. Most GBS cases will be diagnosed in hospital emergency or
neurology departments; the patient’s general practitioner will be
notified upon discharge, potentially several weeks or months after
initial diagnosis. It is thus possible that there could be a considerable
delay between a patient’s initial consultation for neurological
symptoms and the time when a confirmed GBS diagnosis is actually
recorded. As this has implications for defining the exposure period,
we first investigated the temporal relationship between infection and
GBS in cases and controls. Figures 2a–f show incidences of
consultation for the various infections in cases and controls by
month from GBS consultation in cases. No consultations for
cytomegalovirus, H. influenzae or M. pneumoniae were identified; these
exposures were excluded from further analyses. From these figures,
we defined the risk period as 60 days prior to GBS consultation in
cases (or pseudo-outcome date in controls) and excluded individuals
with incomplete UTS time during this period. If one such case was
excluded, all their matched controls were excluded.
The final dataset comprised 553 cases and 5445 matched controls.
We based power calculations on the ability to detect a significant
difference in the prior two-month incidence of Campylobacter infection
between cases and controls. We used data from a community-based
cohort study of IID in England to estimate the two-month incidence
of Campylobacter infection in the general population [31]. Assuming
a conservative value for the between-sets correlation coefficient of
0.2, our study had 90% power to detect a minimum odds ratio of 10
at the 0.05 significance level.
We created indicator variables defining whether or not an
individual had consulted for each of the exposures within the 60-
day risk period. An individual was allowed to contribute only one
consultation per condition during this period, resulting in a set of
binary exposures.
We computed univariate matched odds ratios (ORs) and 95%
confidence intervals (CIs) using conditional logistic regression.
With the exception of one case with influenza-like illness who also
received polio vaccine within the two-month exposure period,
there were no individuals with multiple exposure events (two or
more infections or vaccinations, or infection and vaccination);
multivariable analysis was thus not performed. For GBS patients
with preceding influenza-like illness or polio vaccination, for which
there were sufficient numbers, we compared the median number
of GP consultations for any condition in the 12 months following
GBS diagnosis with that in the 12 months prior to GBS diagnosis
using the Wilcoxon signed-rank test for matched pairs. All analyses
were performed using Stata version 8.0 (StataCorp, Texas).
Figure 2. Incidence of consultation for various infections and influenza vaccination among GBS cases (open bars) and matched controls (dark bars) by
time from GBS consultation in cases. X-axis - time from GBS consultation in cases or pseudo-outcome date in controls (months), y-axis - percentage of
individuals consulting for infections or vaccination.
doi:10.1371/journal.pone.0000344.g002
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Correction for under-ascertainment of
Campylobacter infection
There is considerable under-ascertainment of infection in the
GPRD: not all community Campylobacter enteritis cases present to
general practice and, of those that do, only some are confirmed
microbiologically. Recording of infections in patients’ records may
also be incomplete. The degree of under-ascertainment will vary
between organisms, but is non-differential (independent of case or
control status), as infection is diagnosed prior to GBS. Thus, the
estimate of the OR will, on average, be biased towards the null; for
a given infection incidence, the lower the ascertainment, the
greater the bias [32]. For Campylobacter enteritis, the community
incidence in England is estimated at 8.7 per 1000 personyears
[31]. The incidence in the GPRD population is 0.5 per 1000
personyears. The ratio of GPRD to community incidences
estimates the ascertainment probability for Campylobacter enteritis
(0.058). We assume the specificity to be 1.0, as a culture-confirmed
diagnosis of Campylobacter is unlikely to be false positive.
For a two-by-two table with a exposed cases, b exposed controls,
c unexposed cases and d unexposed controls, the expected number
of truly exposed cases is a/s, where s is the ascertainment
probability. Similarly, b/s gives the expected number of truly
exposed controls. By re-assigning the appropriate number of
individuals from c to a and d to b, a corrected estimate of the true
OR is obtained. This adjustment disregards matching and does
not account for variability in ascertainment; bias could still arise if
ascertainment probability is associated with the matching factors.
The major factor influencing ascertainment is likely to be GP
clinic, as diagnostic practices differ between clinics. We performed
an OR correction by simulating 1000 matched case-control
analyses in which the ascertainment probability for Campylobacter
was fixed within clinics, regardless of case or control status, but
allowed to vary between clinics. We assumed an underlying
population of GP clinics with a true Campylobacter enteritis
incidence of 8.7/1000 personyears. We then obtained GP clinic-
specific incidences of Campylobacter enteritis using standard survival
analysis methods similar to those in our previous GPRD study
[14]. The ratio of these to the true incidence gives a distribution of
ascertainment probabilities, s, across all clinics. The logarithm of
this distribution is approximately Normal with mean 23.01 and
standard deviation 0.76 (data not shown). For each clinic, we
randomly assigned a value of s from this distribution. Within each
clinic, we calculated the probability that an unexposed case
actually had prior Campylobacter infection, (a/s2a)/c, based on this
value of s and conditional values of a and c from the observed
results (table 1, row 1). The corresponding probability for controls
was calculated using the respective values for b and d. These two
probabilities were applied to unexposed individuals within clinics
to randomly re-assign exposure status among cases and controls,
and an OR estimate obtained by conditional logistic regression. A
thousand such simulations were performed to obtain the corrected
OR distribution. The median OR and central 95% range of this
distribution are presented. Comparable community incidence
estimates were unavailable for other organisms; correction for
under-ascertainment of these was not attempted.
Population attributable fraction (PAF)
We estimated the proportion of GBS cases attributable to
Campylobacter as:
PAF~p(OR{1)=OR ½33
where p represents the Campylobacter enteritis prevalence among
cases. We estimated p as the mean number of exposed cases across
the 1000 simulations divided by the total number of cases.
RESULTS
Figures 2a–f show clearly elevated incidences of consultation for
Campylobacter, EBV, ILI, IID and ARI in the two months prior to
GBS consultation in cases compared with controls. No such
difference is apparent for influenza vaccination.
Table 1 presents exposure distributions in cases and controls,
matched ORs, 95% CIs and p-values. For polio vaccination, 16
instances of vaccination were identified among cases, but none
among controls; a lower 95% confidence limit for the OR by exact
likelihood methods, using the PROC LOGISTIC module in SAS
version 9.1 (SAS Institute, North Carolina), was not estimable.
The excess risk of GBS in the two months following Campylobacter
infection, independent of GP clinic, sex, age and season, was 38-
fold (OR=38.4, 95% CI: 4.3–343.5); for EBV, the excess risk was
20-fold. Confidence intervals are wide, reflecting the small number
of these infections identified. Influenza-like illness carried an 18-
fold increase in GBS risk (OR=18.6, 95% CI: 7.5–46.4); for IID
and ARI, the excess risks were seven- and five-fold respectively.
Influenza vaccination appeared protective (OR=0.16, 95% CI:
0.02–1.25), although this result was not significant at the 0.05 level
of precision.
Among GBS patients with influenza-like illness, there were
a total of 256 GP consultations for any condition in the 12 months
following GBS diagnosis, compared with 145 in the 12 months
Table 1. Distribution of preceding infections in GBS cases and controls, and univariate matched ORs and 95% CIs, General Practice
Research Database, United Kingdom 1991–2001
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cases (n = 553) Controls = 5445 95% CI
Exposures No. exposed % No. exposed % Matched OR Lower Upper p
Campylobacter 4 0.72 1 0.02 38.38 4.29 343.54 0.001
Epstein-Barr virus 2 0.36 1 0.02 20.00 1.81 220.56 0.014
Influenza-like illness 14 2.53 9 0.17 18.64 7.49 46.37 ,0.001
Influenza vaccination 1 0.18 47 0.86 0.16 0.02 1.25 0.081
Polio vaccination 16 2.89 0 0.00 – –* –
Infectious intestinal disease 13 2.35 18 0.33 7.26 3.52 14.99 ,0.001
Acute respiratory infection 45 8.14 102 1.87 5.15 3.51 7.58 ,0.001
*The exact conditional likelihood for was not estimable
doi:10.1371/journal.pone.0000344.t001..
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prior to GBS. The difference in the median number of presenta-
tions between these two time periods was highly significant (post-
GBS median= 16, interquartile range (IQR): 10–26; pre-GBS
median = 10, IQR: 4–11, Wilcoxon signed-rank z = 3.13, p =
0.0017). No such difference was found for GBS cases with
preceding polio vaccination.
Corrected Campylobacter estimates
With a fixed under-ascertainment probability of 0.058, the
corrected OR was 44.8. The corrected estimate allowing for
clinic-level matching and ascertainment variability yielded an OR
distribution with median 58.7 and central 95% range 36.9–105.2
(figure 3). One fifth of GBS cases were attributable to Campylobacter
(PAF= 20.1%).
DISCUSSION
We have found strong, positive associations between infection with
Campylobacter, EBV and ILI and GBS risk. Specifically, individuals
with Campylobacter enteritis are 38 times more likely to be diagnosed
with GBS in the subsequent two months, and our correction for
under-ascertainment of Campylobacter infection suggests that the
excess risk could be 60-fold. Approximately 20% of GBS cases are
attributable to Campylobacter infection.
Our results also provide evidence for an 18-fold increased risk of
GBS in the two months following ILI. Such a strong, quantitative
association with ILI has not previously been reported. Given the
high incidence of influenza during epidemic seasons, the burden of
GBS attributable to this organism could be substantial. We found
some evidence of significant excess use of primary care services in
the 12 months following GBS diagnosis among patients with
preceding ILI, with a median of six excess consultations compared
with the 12 month period preceding GBS diangosis. However, this
does not take into account the nature of the consultations and may
not reliably reflect the extent of excess healthcare use, since many
GBS cases may receive follow-up care at hospital outpatient
departments, and these consultations will not appear on their
primary care records. It should be noted that our estimate of the
excess risk of GBS following ILI will be influenced both by under-
ascertainment of true influenza and inclusion of false-positive
influenza, as most cases are not virologically confirmed. In both
these situations, the OR will, on average, be under-estimated; the
true OR could be higher than that observed. As influenza
incidence varies greatly both within and between years, the PAF
for this organism will vary over time. The lower ORs for IID and
ARI are not surprising, as most of these infections will be caused
by pathogens unrelated with GBS.
Unlike previous reports, we found evidence suggesting a pro-
tective effect of influenza vaccination on GBS risk. This finding is
biologically plausible–influenza vaccination provides some pro-
tection against influenza infection and, hence, associated compli-
cations. It is, however, also possible that the protective effect of
influenza vaccination is a result of individuals suffering a recent
acute infection being less likely to be offered vaccine. As there were
no individuals who both suffereed ILI and received vaccine within
the exposure period, we were unable to investigate this possibility.
Historical cohort studies of primary care data comparing GBS risk
among vaccinees and non-vaccinees would be better suited to
address this. The apparent protective effect of vaccine found here
is not inconsistent with an absolute increase in GBS risk following
influenza vaccination, but indicates that this is much smaller than
the risk associated with influenza infection. The balance between
GBS risk and protection from vaccine will reflect the frequency of
influenza in a given season. The exact vaccine formulation could
also influence risk. An association with polio vaccination was also
apparent, although it should be noted that while most such
vaccinations take place among young children, the majority of
GBS cases occur in older individuals. It is thus unlikely that polio
vaccination accounts for a substantial proportion of GBS cases in
the UK. Historical cohort studies, as described above for influenza
vaccination, could yield further insight into the association
between GBS and polio vaccination, and could in addition
investigate the effect of vaccine dosage.
Our study has certain limitations. Individuals consulting general
practice are symptomatic. Evidence suggests that, at least for
Campylobacter, GBS may arise following asymptomatic infection
[34]; we could not address this in our study. Other than age and
sex, GPRD data contain little information on potential con-
founders, such as geographic location and socioeconomic status;
we addressed this by matching on GP clinic. Due to under-
ascertainment of infections, our estimates are likely to be biased
towards the null. For Campylobacter enteritis, for which a reliable
estimate of community incidence exists, we corrected for this by
accounting for the magnitude and variability of ascertainment at
clinic level, the factor most likely to influence ascertainment. Some
residual bias might remain through ascertainment differences by
sex and/or age. Although such residual bias could affect the
magnitude of bias in the OR, it is unlikely to affect its direction
unless ascertainment is differential (dependent on case status) in
one or more age/sex strata. We think this highly unlikely, as in our
study infection was determined before GBS. Our correction
additionally assumes that clinic-level variation in Campylobacter
incidence is entirely due to ascertainment differences rather than
differences in true incidence. These two factors cannot be
disentangled without knowledge of the variation in true Campylo-
bacter incidence across clinics. Given the low ascertainment in all
GP clinics, we believe this assumption is reasonable.
Our analysis has several advantages over previous GBS risk
factor studies. Firstly, we used a representative sample of cases and
controls from the UK population; our results are more generaliz-
able than those of studies conducted in hospital settings. Secondly,
although our study suffered from under-ascertainment of infec-
tions, this was non-differential. By contrast, exposure misclassifi-
cation in studies using serology to determine prior Campylobacter
Figure 3. Distribution of corrected OR for the association between
Campylobacter enteritis and GBS, based on 1000 simulations with
varying values of clinic-level ascertainment of Campylobacter infection
(see text).
doi:10.1371/journal.pone.0000344.g003
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infection cannot be expected to be non-differential. Evidence
suggests that following Campylobacter infection, antibody levels
remain elevated for several months and even years [35–37]. The
temporal association between Campylobacter and GBS means that
seropositivity in GBS cases is more likely to indicate true recent
infection, while in controls it could signify recent infection, past
infection, or immunity. Such studies thus overestimate the
incidence of recent infection in controls relative to cases, yielding
ORs substantially below those observed in our study.
Our findings indicate the value of primary care data for studying
rare complications of infectious diseases. Although ascertainment of
infections can be low, figure 2 clearly demonstrates that such systems
are sensitive for detecting temporal associations between infection
and sequelae. We recommend more widespread use of such systems
for surveillance purposes. The data are routinely available, con-
siderably cheaper than the operating costs for a dedicated surveil-
lance system, and particularly advantageous for rare conditions.
There are also considerable advantages for observational studies;
cases are effectively nested within a cohort, minimizing the risk of
selection, recall and diagnostic biases, common problems in
conventional case-control studies.
Using this strategy, we have detected two novel findings: an
increased risk of GBS following ILI and a possible protective effect
of influenza vaccination. Clinicians should consider recent history
of influenza as a possible triggering factor in GBS cases. Our
findings also suggest that influenza vaccination may provide
additional, indirect effects through protection against complica-
tions of influenza infection. Further studies to determine the
incidence of GBS following both vaccination against and infection
with influenza are warranted.
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